Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

Core Viewpoint - Alnylam Pharmaceuticals has announced a private offering of $575 million in convertible senior notes due 2028, targeting qualified institutional buyers under Rule 144A of the Securities Act [1] Group 1 - The offering consists of 0.00% convertible senior notes, indicating a non-interest-bearing structure [1] - The size of the offering was increased, reflecting strong demand from the market [1]